Recent Updates
Recently added Catalysts

polymixin/bacitracin

Phase 3

Sick Sinus Syndrome | Small molecule | Cardiovascular |The Cooper Companies, Inc.|Last Updated: May 9, 2022

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedACTIVE_CONTROLLED
Total Trials1
Total Enrollment1,010
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT02809131Perioperative Antibiotic Therapy to Prevent Cardiac Implantable Electronic Device Infections.PHASE3 COMPLETED 1,010Apr 1, 2016Sep 30, 2021May 9, 20221 United States
Unlock Drug Trial Details
Study Endpoints
Primary Endpoints
Number of Patients With a Major Cardiac Implantable Electronic Devices (CIED) Infection
6 months

The primary study endpoint will be the number of patients with CIED infection resulting in complete CIED system removal, antibiotic therapy in patients who are not candidates for system removal, or death due to CIED infection.

Secondary Endpoints
Number of Patients With a Minor Cardiac Implantable Electronic Devices (CIED) Infection
6 months
Unlock Study Endpoints
Study Design & Arms
AllocationRANDOMIZED
MaskingNONE
ModelPARALLEL
PurposePREVENTION
Treatment Arms
ArmTypeDescription
Saline irrigationEXPERIMENTALSaline irrigation
Antibiotic irrigation and PO antibioticsACTIVE_COMPARATORAntibacterial irrigant (polymyxinB/bacitracin) and postoperative oral antibiotics (cephalexin, clindamycin, or levofloxacin)
Interventions
NameTypeDescription
polymixin/bacitracinDRUGAntibacterial irrigation
cephalexin, or levofloxacin, or clindamycinDRUGPost operative oral antibiotics
SalineDRUGSaline irrigation
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years — N/A
SexALL
Healthy VolunteersNo
Study Sites1

Inclusion Criteria: * Age ≥18 years old * Able to give informed consent * At least 2 of the following risk factors for infection: * Diabetes mellitus * Chronic kidney disease (estimated creatinine clearance \<30 ml/min * Therapeutic anticoagulation * Chronic heart failure * Chronic use o...

Countries:United States
Unlock Eligibility Criteria